Plan: OPEN | Option: Growth | Sailesh Raj Bhan

28 Sep 20 | 12:00 AM

225.87 3.41 (1.53%)

  • Underperforms

    59.07%

    Return (1Y)

    underperformed S&P BSE Healthcare TRI by -0.82%

  • Less Volatile

    1.58%

    Standard Deviation (1Y)

    Lower Equity - Pharma by -0.41%

  • Not so consistent

    5/12

    Months

    Has beaten Equity - Pharma

  • Value research rating

    Not Rated

Stock Composition

NAV

Scheme Trivia

  • Reliance Pharma Fund (G) fund has been the 5th best in 5Y performance in the Equity - Pharma category

  • Reliance Pharma Fund (G) fund has been given the 6th best Risk adjusted performance for the past 5Y in the Equity - Pharma category

  • Reliance Pharma Fund (G) fund has been the 5th best in the 5Y SIP performance in the Equity - Pharma category

Critical Parameters

Everyone of us wants to create wealth by investing in top funds. Have a look at the key parameters that you need to check before deciding to invest in a mutual fund.

Returns

In last 1 year Nippon India Pharma Fund (G), has beaten by -0.82% (CAGR difference)

59.07%

Underperforms

This is Alpha

Performance Chart for Rs

Invested in

Risk

In last 1 year , the volatility of Nippon India Pharma Fund (G) is Lower than by -0.41%

1.58%

Less Volatile

Risk Meter

Peer Comparison on Risk - Return

Consistency

For 5 out of Last 12 Months, i.e 41.67% of the times It beaten its benchmark, Equity - Pharma

Consistency Meter

Outperforming Stocks Vs. Underperforming Stocks

Based on the last 1year analysis, currently there are, the benchmark the benchmark

View Stock Composition